№ files_lp_4_process_3_104526
File format: docx
Character count: 3601
File size: 724 KB
Structured clinical source detailing the sequence of care, medical management, monitoring, and debrief outcomes for severe preeclampsia and hypertension in pregnant and postpartum patients within a hospital setting in Illinois.
Year:
2026
Region / City:
Illinois, USA
Topic:
Preeclampsia management and severe hypertension response
Document Type:
Clinical review and debrief form
Institution:
Hospital maternity services
Authors:
Maternity service team
Target Audience:
Healthcare providers managing obstetric patients
Patient Population:
Pregnant and postpartum women up to 6 weeks
Date of Document:
2026
Data Collection Period:
Within 24 hours of severe hypertension events
Clinical Measures:
Blood pressure management, medication administration, maternal and neonatal outcomes
Transport Information:
Intra- and inter-hospital transfer details
Debrief Participants:
Primary RN and Primary MD
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
United States
Topic:
Maternal Health / Postpartum Care
Document Type:
Clinical Counseling Script
Organization / Institution:
Hospital or Healthcare Facility
Author:
Registered Nurse / Healthcare Provider Team
Target Audience:
Patients with preeclampsia, postpartum preeclampsia, eclampsia, or HELLP syndrome and their families
Relevant Period:
Postpartum and immediate recovery period
Date Approved:
2026-03-03
Medications Discussed:
Magnesium Sulfate, Antihypertensives
Procedures / Imaging:
Blood pressure monitoring, specialist consultations
Specialists Involved:
Obstetrician, Cardiologist, Neurologist (if seizures occurred)
Note:
Year
Subject:
Immigration and Refugee Status Verification
Document Type:
Guide
Document Type:
Clinical Guidelines
Authors:
Dr Bethan McMinn Consultant Community Paediatrician; Dr Klara Brzyska Paediatric ST4
Approval / Effective Date:
01/01/2023
Review Date:
01/01/2025
Version:
1
Target Audience:
People who need to know about this document in detail
Note:
Paediatricians (acute and community)
Disclaimer:
If the review date of this document has passed, please ensure that the version you are using is the most up to date version either by contacting the author.
Year:
2023
Region / City:
East Anglia, Wales
Theme:
Early Developmental Impairment, Intellectual Disability, Paediatric Assessment
Institution:
Cwm Taf Morgannwg University Health Board
Author:
Dr Bethan McMinn, Dr Klara Brzyska
Period of validity:
01/01/2023 - 01/01/2025
Approval Date:
01/01/2023
Year:
1998–2004
Region / City:
Baltimore, New York
Topic:
Communication, Special Education, Disability Support
Document Type:
Educational Guide / Reference
Institution / Organization:
Paul H. Brookes Publishing Co., Charles E. Merrill
Authors:
Downing, J.E.; Beukelman, D.R.; Mirenda, P.; Orelove, F.P.; Sobsey, D.; Snell, M.E.; Brown, F.
Target Audience:
Educators, Special Education Professionals
Period Covered:
Late 20th – early 21st century
Communication Types:
Receptive, Expressive, Symbolic, Nonsymbolic
Instructional Focus:
Strength-based approaches, observation skills, augmentative and alternative communication methods
Reference Systems:
Picture symbols, sign language, Braille, verbal speech, object cues, gestures, switch activation
Year:
2021
Region / City:
United Kingdom
Subject:
Health economics, antimicrobial evaluation
Document type:
Final report
Organization / Institution:
Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author:
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience:
Healthcare professionals, policymakers, researchers
Period of validity:
2016 - ongoing
Approval date:
October 2021
Date of last modification:
October 2021
Year:
Not specified
Region / City:
North Northamptonshire
Topic:
Mental Health, Severe Mental Illness, Social Care
Document Type:
Request for Quotation (RFQ)
Organization / Institution:
North Northamptonshire Council
Author:
Not specified
Target Audience:
Potential suppliers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Canberra Health Services Guideline Apixaban and Rivaroxaban Use in Adults with Severe Kidney Disease
Year:
2021
Region / City:
Canberra, Australia
Topic:
Pharmacology / Kidney Disease
Document Type:
Clinical Guideline
Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical staff and pharmacists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2017–2021
Medical field:
Sleep medicine
Condition:
Moderate to severe obstructive sleep apnea
Intervention:
Hypoglossal nerve stimulation
Procedure codes:
64582, 64583, 64584
Type of document:
Evidence review and policy summary
Reviewing bodies:
NICE; VbBS; HERC
Last review date:
November 2021
Study types included:
Systematic review; randomized controlled trial; prospective and retrospective case series
Number of studies:
7
Total patients:
326
Geographic context:
United Kingdom; United States
Regulatory context:
Clinical governance and payer policy assessment
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Year:
2025
Region / City:
UK
Topic:
Healthcare, Medication Guidelines
Document Type:
Medical Protocol
Organisation:
National Ambulance Service Medical Directors (NASMeD)
Author:
Dr. Elizabeth Miller, Dr. Dave Macklin, Mr. Andy Curran, Rosie England, Cathryn James, Dan Haworth, Tracy Rogers, Jo Jenkins, Rosie Furner
Target Audience:
Registered healthcare professionals, Paramedics, Nurses, Midwives
Effective Date:
May 2023
Review Date:
October 2025
Expiry Date:
April 2026
Approval Date:
May 2025
Change History:
Includes updates to drug administration protocols and clinical guidelines
Year:
2023
Region / City:
Australia
Topic:
Hidradenitis Suppurativa Treatment
Document Type:
Submission for Pharmaceutical Benefits Scheme (PBS) Listing
Organ / Institution:
Novartis Pharmaceuticals Australia Pty Limited
Author:
Novartis Pharmaceuticals Australia Pty Limited
Target Audience:
Medical professionals, Healthcare policymakers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Category / Program:
General Schedule (Code GE)
Prescriber Type:
Dental Medical Practitioners, Nurse Practitioners, Optometrists, Midwives
Restriction Type:
Authority Required
Severity:
Moderate to severe
Condition:
Hidradenitis suppurativa
Treatment Phase:
Initial treatment
Clinical Criteria:
Hurley stage II or III grading, abscess and inflammatory nodule count ≥ 3, failure to respond to antibiotics
Treatment Criteria:
Dermatologist supervision
Population Criteria:
Adult patients
Administrative Advice:
Subcutaneous injection
Prescribing Instructions:
Must assess disease severity, first 4 weeks under restriction
Cost:
$6,145.10 for 300 mg/2 mL pre-filled syringe/pen
Source:
Table 1.1, p25; Table 1.6, p35; Table 1.7, pp36-37; Table 1.7, p38
Year:
2019
Region / City:
United Kingdom
Topic:
Chronic Obstructive Pulmonary Disease (COPD), Oxygen Saturation
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target Audience:
General practitioners, healthcare professionals
Period of Validity:
Not specified
Approval Date:
August 2019
Date of Last Update:
N/A
Year:
2022-2023
Region / City:
Florida
Topic:
Education, Special Education, Accessibility
Document Type:
Official guideline
Organization:
Florida Department of Education (FLDOE)
Author:
Not specified
Target Audience:
Case managers, educators, IEP team members
Period of validity:
Ongoing, annual requests
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2022
Region / City:
York
Theme:
Special Education, Curriculum Design
Document Type:
Educational Policy
Organization / Institution:
Applefields School
Author:
Applefields School Leadership Team
Target Audience:
Educators, Special Education Professionals, Parents of Students with Severe Learning Difficulties
Period of Validity:
Ongoing
Approval Date:
2022
Modification Date:
Ongoing
Year:
2017
Region / City:
Emergency Department
Topic:
Severe Sepsis, Septic Shock, Patient Rescreening
Document Type:
Advisory, Medical Alert
Institution:
UCLA
Author:
Not specified
Target Audience:
Emergency Department Nurses
Action Period:
3/3/17 – proposed changes
Approval Date:
Not specified
Modification Date:
3/24/17
Context:
A guideline for the early identification and rescreening of patients at risk for severe sepsis or septic shock in an emergency department setting, with detailed criteria for triggers and actions.
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2020
Region / City:
North West London
Theme:
Maternity care, apprenticeship training
Document Type:
Training manual
Institution:
London North West University Healthcare NHS Trust, Imperial College Healthcare NHS Trust, The Hillingdon Hospitals NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust
Author:
Not specified
Target Audience:
Maternity support workers
Period of Validity:
Throughout apprenticeship program
Approval Date:
January 2020
Date of Changes:
Not specified
Year:
2023
Region / city:
United Kingdom
Subject:
Maternity care, neonatal care, e-learning
Document type:
Guide
Institution:
Health Education England
Author:
Health Education England
Target audience:
Healthcare professionals in maternity and neonatal care
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2025
Region / City:
Wales
Theme:
Healthcare, Maternity Services, Neonatal Services
Document Type:
Report
Organization:
Health Board, Welsh Government
Author:
Liz Wonnacott, Head of Service – Medical Director
Target Audience:
Healthcare professionals, Government officials, Quality assurance bodies
Period of Validity:
Ongoing
Approval Date:
15 May 2025
Date of Amendments:
May 2025
Year:
2021
Region / City:
East of England
Theme:
Maternity care, Neonatal care
Document Type:
Incident Report
Organization / Institution:
NHS
Author:
Not specified
Target Audience:
Healthcare professionals in maternity and neonatal care
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Modifications:
July 2021
Context:
This document outlines a protocol for reporting incidents related to preterm delivery at a maternity unit without NICU facilities, aimed at healthcare providers within the East of England region.